CS
LGND icon

Candriam SCA’s Ligand Pharmaceuticals LGND Stock Holding History

Candriam SCA’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,546
Closed -$905K – 906
2022
Q4 		$905K Buy
+13,546
New +$881K 0.01% 714
2019
Q3 		– Sell
-24,045
Closed -$1.71M – 781
2019
Q2 		$1.71M Hold
24,045
– – 0.02% 553
2019
Q1 		$1.89M Hold
24,045
– – 0.02% 512
2018
Q4 		$2.04M Buy
+24,045
New +$2.56M 0.03% 459

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's LGND Position: Q1 2023 in Review

Candriam SCA sold out of Ligand Pharmaceuticals (LGND) in Q1 2023, closing a stake of 13,546 shares — an estimated $905K sold.

Candriam SCA first reported a position in LGND in Q4 2018 and held it in 4 quarters. The position peaked at $2.04M in Q4 2018. 212 funds tracked by Wall St. Rank hold LGND as of Q1 2023.

  • Candriam SCA reported no remaining Ligand Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 13,546 Ligand Pharmaceuticals shares in Q1 2023, an estimated $905K.
  • Candriam SCA first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Candriam SCA's Ligand Pharmaceuticals position peaked at $2.04M in Q4 2018.
  • 212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.